NCT00034684已完成1 期
Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 132
研究概览
简要总结
The purpose of this study is to determine the safety and tolerability of an oral Farnesyl Protein Transferase Inhibitor (SCH 66336) as a single agent in patients with Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia in Blast Crisis, or Acute Lymphoblastic Leukemia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologically documented chronic myelogenous leukemia in blast crisis, myelodysplasia, acute myelogenous leukemia, or acute lymphocytic leukemia.
- •Life expectancy of 12 weeks or greater.
- •ECOG Performance Status less than or equal to
- •Meets protocol requirements for specified laboratory values.
- •No manifestations of a malabsorption syndrome.
排除标准
- •Patients who have received more than three chemotherapy regimens for more than three recurrences of the disease.
- •Poor medical risks because of nonmalignant systemic disease as well as those with active uncontrolled conditions.
- •Patients who have received investigational therapy of any type within 30 days prior to administration.
研究者
相似试验
终止
1 期
Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination With Gemcitabine and Cisplatin in Advanced Cancer (Study P01499)(TERMINATED)NeoplasmsNCT00040534Merck Sharp & Dohme LLC22
已完成
1 期
Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors (Study P01964)(COMPLETED)NeoplasmsNCT00040547Merck Sharp & Dohme LLC29
Unknown
1 期
Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)CancerNCT00006199National Center for Research Resources (NCRR)
终止
2 期
Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)Carcinoma, Squamous CellHead and Neck NeoplasmsNCT00073450Merck Sharp & Dohme LLC15
已完成
2 期
Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's DiseaseMild Cognitive ImpairmentAlzheimer's DiseaseNCT01661673FORUM Pharmaceuticals Inc52